

b.) Remarks

Claim 1 has been amended to more specifically recite the subject matter of the present invention. Claim 25 is amended in conformity therewith. Additionally, claims 71 and 72 are added in order to recite various preferred embodiments of the present invention and claims 24, 31, 69 and 70 are cancelled. The subject matter of the amendment is found in the specification as filed at page 47, line 7 and Test Examples 1, 4, 5, 8 and 10. Accordingly, no new matter has been added.

As discussed in Applicants' June 2, 2009 Amendment, the Goodman and Gilman reference teaches

- (1) "Antidepressants, especially serotonin-reuptake inhibitors, also are employed in the management of post-traumatic stress disorder, marked by anxiety"<sup>1</sup>;
- (2) "For panic disorder, tricyclic antidepressants and MAO inhibitors, as well as high-potency benzodiazepines (notably alprazolam, clonazepam, and lorazepam; see Chapter 17) are effective in blocking the autonomic expression of panic itself"<sup>2</sup>;
- (3) "The serotonin-reuptake inhibitors also may be effective, but β-adrenergic receptor antagonists, buspirone, and low-potency benzodiazepines usually are not, and bupropion can worsen anxiety"<sup>3</sup>; and lastly
- (4) "The serotonin-reuptake inhibitors are agents of choice in obsessive-compulsive disorder ..... While their benefits may be limited, serotonin-reuptake inhibitors

---

<sup>1</sup> See, lines 1-3 of p. 469, right column.

<sup>2</sup> See, lines 11-14 of p. 469, right column.

<sup>3</sup> See, lines 19-22 of p. 469, right column.

offer an important advance in the medical treatment of these often chronic and sometimes incapacitating disorders”<sup>4</sup>.

From the above teaching, Goodman & Gilman’s teaches that specific antidepressants may be used for treating PTSD, panic disorder, generalized anxiety disorder, social phobia and obsessive-compulsive disorder. However, as discussed above, Goodman does not teach or address treatment of generalized anxiety disorder. Nor, in any event, is Applicants’ Compound A is a serotonin-reuptake inhibitor (c.f., Goodman points 1, 3 and 4), tricyclic antidepressant, MAO inhibitor or a benzodiazepine (c.f., Goodman point 2) anyway.

Entry hereof is earnestly solicited.

Applicants’ undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

/Lawrence S. Perry/

Lawrence S. Perry  
Attorney for Applicants  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

LSP\ac

FCHS\_WS 3593272\_1.DOC

---

<sup>4</sup> See, lines 24-34 of p. 469, right column.